期刊文献+

小肠胃肠间质瘤64例治疗与预后分析 被引量:6

Treatment and prognosis of gastrointestinal stromal tumor in small intestine: an analysis of 64 patients
原文传递
导出
摘要 目的探讨小肠胃肠间质瘤(GIST)的治疗及预后影响因素。方法回顾性分析天津医科大学附属肿瘤医院2002年4月至2010年11月收治的经手术治疗且有完整随访资料的64例小肠GIST患者的临床和随访资料。结果全组患者术后均未接受化、放疗.有14例患者术后予以伊马替尼靶向治疗。64例小肠GIST患者5年生存率为51.2%;61例R0切除患者术后复发转移27例(44.3%)。单因素预后分析显示,手术方式(P=0.001)、肿瘤大小(P=0.018)、周围组织粘连侵犯(P=0.015)、伴发远处转移(p=0.000)、肿瘤坏死出血(p=0.032)、F1etcher分级(P=0.027)及就诊时症状(p=0.012)与小肠GIST患者预后有关。多因素预后分析显示,周围组织粘连侵犯(P=0.026)、伴发远处转移(P=0.000)和就诊时症状(P=0.019)是小肠GIST患者预后的独立影响因素。结论评估小肠GIST患者的预后,应结合手术方式、肿瘤大小、与周围组织脏器有无粘连侵犯、有无伴发远处转移、有无肿瘤坏死出血、就诊时症状、Fletcher分级以及靶向治疗情况进行多方面考虑。 Objective To investigate treatment and prognostic factors of gastrointestinal stromal tumor (GIST) in the small intestine. Methods The clinicopathological data of 64 patients with GIST in the small intestine admitted to the Tianjin Medical University Affiliated Cancer Hospital between April 2002 and November 2010 were analyzed retrospectively and the prognostic factors were evaluated. Results No patients in this cohort received chemotherapy or radiation therapy. Fourteen patients underwent post-operative imatinib targeted therapy. The overall 5-year survival rate was 51.2% and the post-operative recurrence rate of 61 cases undergoing R0 resection was 44.3%. Univariate analysis revealed that the complete tumor resection (P=0.001), tumor size (P=0.018), adhesion or invasion to surrounding tissue and organs (P=0.015), concurrent distant metastasis (P=0.000), tumor hemorrhage (P=0.032), Fletcher classification (P=0.027) and symptom (P=0.012) were associated with prognosis. Multivariate analysis demonstrated that adhesion or invasion to surrounding tissue and organs(P=0.026), concurrent distant metastasis (P=O.000) and symptom (P=0.019) were independent prognostic factors for survival. Conclusion The survival evaluation of patients with small intestinal GIST depends on surgery, tumor size, adhesion or invasion to surrounding tissue and organs, concurrent distant metastasis, tumor hemorrhage, symptom, Fletcher classification, and use of targeted therapy.
出处 《中华胃肠外科杂志》 CAS 2012年第3期259-262,共4页 Chinese Journal of Gastrointestinal Surgery
关键词 胃肠间质瘤 小肠 外科手术 预后 伊马替尼 Gastrointestinal stromal tumors, small intestine Surgical procedures Prognosis Imatinib
  • 相关文献

参考文献15

  • 1Miettinen M, Sobin LH, Lasota J. Gastrointestinal stromaltumors of the stomach: a chn icopathologlc, immunohistochemical, and molecular genetic study of 1765 cases with long term follow-up. Am J Surg Pathol, 2005,29 ( 1 ) : 52-68. 被引量:1
  • 2Fletcher CD, Berman JJ, Corless C, et al. Diagnosis of gastrointestinal stromal tumors: A consensus approach. Hum Pathol, 2002,33 (5) : 459-465. 被引量:1
  • 3王刚,张汝鹏,赵敬柱,王学军,柯彬.132例胃的胃肠间质瘤治疗及预后分析[J].中华胃肠外科杂志,2010,13(7):492-496. 被引量:19
  • 4Rossi S, Miceli R, Messerini L, et al. Natural history of imatinib-naive GISTs: a retrospective analysis of 929 cases with long-term follow-up and development of a survival nomogram based on mitotic index and size as continuous variables. Am J Surg Pathol, 2011,35(11):1646-1656. 被引量:1
  • 5何裕隆.胃肠间质瘤临床病例解析[J].国际外科学杂志,2007,34(5):354-358. 被引量:12
  • 6Cichoz-Lath H, Kasztelan-Szczerbinska B, Slomka M Gastrointestinal stromal tumors : epidemiology, clinical picture, diagnosis, prognosis and treatment. Pol Arch Med Wewn, 2008,118(4) :216-221. 被引量:1
  • 7Huang H, Liu YZ, Zhan ZL, et al. Different sites and prognoses of gastrointestinal stromal tumors of the stomach: report of 187 cases. World J Surg, 2010,34(7):1523-1533. 被引量:1
  • 8Hassan I, You YN, Shyyan R, et al. Surgically managed gastrointestinal stromal tumors a comparative and prognostic analysis. Ann Surg Oncol, 2008,15 ( 1 ) : 52-59. 被引量:1
  • 9Demetri GD, BenjaminRS, Blanke CD, et al. NCCN Task Force report: management of patients with gastrointestinal stromal tumor (GIST)-update of the NCCN clinical pactice guidelines. J Natl Compr canc Netw, 2007,5 (Suppl 2) :S 1-$30. 被引量:1
  • 10Dematteo RP, Ballman KV, Antonescu CR, et al. Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. Lancet, 2009,373 (9669) : 1097- i 104. 被引量:1

二级参考文献22

  • 1白月奎,邵永孚,石素胜,高燕宁,孙耘田,程书钧,刘秀云.胃肠道间质瘤预后多因素分析[J].中华肿瘤杂志,2005,27(10):598-601. 被引量:22
  • 2詹文华,王鹏志,邵永孚,伍晓汀,顾晋,李荣,万德森,丁克峰,师英强,于吉人,卢辉山,邹小明,毕建威,孙益红,陆云飞,陈道达,张信华.伊马替尼术后辅助治疗胃肠间质瘤的多中心前瞻性临床试验中期报告[J].中华胃肠外科杂志,2006,9(5):383-387. 被引量:85
  • 3Cichoz-Lach H,Kasztelan-Szczerbinska B,Slomka M.Gastrointestinal stromal tumors:epidemiology,clinical picture,diagnosis,prognosis and treatment.Pol Arch Med Wewn,2008,118(4):216-221. 被引量:1
  • 4Fletcher CD,Berman JJ,Corless C,et al.Diagnosis of gastrointestinal stromal tumors:A consensus approach.Hum Pathol,2002,33(5):459-465. 被引量:1
  • 5Bauer S,Corless CL,Heinrich MC,et al.Response to imatinib mesylate of a gastrointestinal stromal tumor with very low expression of KIT.Cancer Chemother Pharmacol,2003,51(3):261-265. 被引量:1
  • 6Mochizuki Y,Kodera Y,Ito S,et al.Treatment and risk factors for recurrence after curative resection of gastrointestinal stromal tumors of the stomach.World J Surg,2004,28(9):870-875. 被引量:1
  • 7Carboni F,Carlini M,Scardamaglia F,et al.Gastrointestinal stromal tumors of the stomach.A ten-year surgical experience.JExp Clin Cancer Res,2003,22(3):379-384. 被引量:1
  • 8DeMatteo RP,Lewis JJ,Leung D,et al.Two hundred gastrointestinal stromal tumors:recurrence patterns and prognostic factors for survival.Ann Surg,2000,231 (1):51-58. 被引量:1
  • 9Croom KF,Perry CM.Imatinib mesylate:in the treatment of gastrointestinal stromal tumours.Drugs,2003,63(5):513-524. 被引量:1
  • 10Miettinen M,Sobin LH,Lasota J.Gastrointestinal stromal tumors of the stomach:a clinicopathologic,immunohistochemical,and molecular genetic study of 1765 cases with long-term follow-up.Am J Surg Pathol,2005,29(1):52-68. 被引量:1

共引文献31

同被引文献46

  • 1冯关荣.胃肠道间质瘤的诊治现状[J].医学文选,2006,25(2):322-323. 被引量:7
  • 2师英强,梁小波,等.胃肠道间质瘤.北京:人民卫生出版社,2011,3:62-67. 被引量:3
  • 3Huang H, Liu YX, Zhan ZL, et al. Different sites and prognoses of gastrointestinal stromal tumors of stomach: report of 187 cases. World J Surg ,2010,34 (7) : 1523-1533. 被引量:1
  • 4Takiguchi S, Masuzawa T, Hirao T, et al. Pattern of surgical treatment for early gastric cancer in upper third of the stomach. Hepatogastroenterology ,2011,58 ( 110-111 ) : 1823-1827. 被引量:1
  • 5NCCN. The NCCN soft tissue sarcoma clinical practice guidelines in oncology ( version 1. 2011 ) [ EB/OL ]. Fort Washington: NCCN, 2011 [2011-07-29]. http://www, nccn. org/professionals/physi- cian-gls/f-guidelines, asp. 被引量:1
  • 6Joensuu H, Eriksson M, Hartmann J, et al. Twelve vs 36 months of adjuvant imatinib ( IM ) as treatment of operable GIST with a high risk of recurrence : final results of a randomized trial ( SSGX- VIII/AIO). J Clin Oneol 2011,29( 15 Suppl):LBA1. 被引量:1
  • 7Joensuu H. Risk stratification of patients diagnosed with gastroin- testinal stromal tumors. Hum Pathol,2008,39(10) :1411-1419. 被引量:1
  • 8Hirota S, Isozaki K, Moriyama Y, et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors [J]. Science, 1998,279:577-580. 被引量:1
  • 9Liegl B, Homick JL, Gutless CL, et al. Monoclonal antibody DOG1 shows higher sensitvty than KIT in the diagnosis of gastrointestinal stromal tumors,including unusual subtypes [J]. Am J Surg Pathol, 2009,33:437-446. 被引量:1
  • 10Agaram NP, Wang GC, Guo T, et al. Novel V600E BRAF mutations in imatinib-naive and imatinib-resistant gastrointestinal stromal tumors[J]. Genes Chromosomes Cancer, 2008,47:853- 859. 被引量:1

引证文献6

二级引证文献19

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部